首页> 外文期刊>The American heart journal >Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure
【24h】

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure

机译:结合使用高敏感性心肌肌钙蛋白T和N端pro-B型利钠尿肽可改善对慢性心力衰竭已确立的死亡危险因素的绩效测量

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Heart failure still maintains a high mortality. Biomarkers reflecting different pathophysiological pathways are under evaluation to better stratify the mortality risk. The objective was to assess high-sensitivity cardiac troponin T (hs-cTnT) in combination with N-terminal pro-B type natriuretic peptide (NT-proBNP) for risk stratification in a real-life cohort of ambulatory heart failure patients. Methods: We analyzed 876 consecutive patients (median age 70.3 years, median left ventricular ejection fraction 34%) treated at a heart failure unit. A combination of biomarkers reflecting myocyte injury (hs-cTnT) and myocardial stretch (NT-proBNP) was used in addition to an assessment based on established mortality risk factors (age, sex, left ventricular ejection fraction, New York Heart Association functional class, diabetes, estimated glomerular filtration rate, ischemic etiology, sodium, hemoglobin, β-blocker treatment, and angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment). Results: During a median follow-up of 41.4 months, 311 patients died. In the multivariable Cox proportional hazards model, hs-cTnT and NT-proBNP were independent prognosticators (P =.003 each). The combined elevation of both biomarkers above cut-off values significantly increased the risk of death (HR 7.42 [95% CI, 5.23-10.54], P <.001). When hs-cTnT and NT-proBNP were individually included in a model with established mortality risk factors, measurements of performance significantly improved. Results obtained for hs-cTnT compared with NT-proBNP were superior according to comprehensive discrimination, calibration, and reclassification analysis (net reclassification indices of 7.7% and 1.5%, respectively). Conclusions: hs-cTnT provides significant prognostic information in a real-life cohort of patients with chronic heart failure. Simultaneous addition of hs-cTnT and NT-proBNP into a model that includes established risk factors improves mortality risk stratification.
机译:背景:心力衰竭仍然保持较高的死亡率。反映不同病理生理途径的生物标志物正在评估中,以更好地对死亡风险进行分层。目的是评估高灵敏度的心脏肌钙蛋白T(hs-cTnT)与N端pro-B型利钠肽(NT-proBNP)的结合,以评估动态性心衰患者的真实队列中的风险分层。方法:我们分析了在心力衰竭单元接受治疗的876例连续患者(中位年龄70.3岁,中位左心室射血分数34%)。除了根据既定的死亡风险因素(年龄,性别,左心室射血分数,纽约心脏协会功能类别,确定的死亡风险因素)进行评估之外,还使用了反映心肌细胞损伤(hs-cTnT)和心肌牵张(NT-proBNP)的生物标志物组合。糖尿病,估计的肾小球滤过率,缺血性病因,钠,血红蛋白,β受体阻滞剂和血管紧张素转化酶抑制剂或血管紧张素II受体阻断剂治疗)。结果:在中位随访41.4个月中,有311例患者死亡。在多变量Cox比例风险模型中,hs-cTnT和NT-proBNP是独立的预后因子(每个P = 0.003)。两种生物标志物的总升高超过临界值会显着增加死亡风险(HR 7.42 [95%CI,5.23-10.54],P <.001)。当将hs-cTnT和NT-proBNP分别包含在具有确定的死亡危险因素的模型中时,性能的测量会显着提高。根据综合的判别,校正和重新分类分析,hs-cTnT与NT-proBNP相比获得的结果更好(净重新分类指数分别为7.7%和1.5%)。结论:hs-cTnT为慢性心力衰竭患者的真实队列提供了重要的预后信息。将hs-cTnT和NT-proBNP同时添加到包含已建立风险因素的模型中,可以改善死亡率风险分层。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号